Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment
BACKGROUND: Autoantibodies are common in glomerulonephritis, but the clinical benefit of rapid elimination is not determined, even in anti-glomerular basement membrane (GBM) disease. Even less is known about the importance of autoantibody characteristics, including epitope specificity and IgG subclass distribution. By utilizing samples from the GOOD-IDES-01 trial, where imlifidase, cleaving all Ig